Progress against solid tumors in danger: The metastatic breast cancer example

Journal of Clinical Oncology

Volumn 30, Issue 28, 2012, Pages 3444-3447

  Corteś, Javier ^a   Calvo, Emiliano ^b   González Martín, Antonio ^c   Dawood, Shaheenah ^d   Llombart Cussac, Antonio ^e,f   De Mattos Arruda, Leticia ^a   Gómez, Patricia ^a   Silva, Orlando ^g   Perez, Edith A ^h   Rugo, Hope S ⁱ   Lluch, Ana ^j   Hortobagyi, Gabriel N ^k  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HM Hospitales Centro Integral Oncológico Hospital de Madrid Clara Campal   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

^d DUBAI HEALTH AUTHORITY   (United Arab Emirates)

^e HOSPITAL ARNAU DE VILANOVA   (Spain)

^f Academic Research Organization   (Spain)

^g UNIVERSITY OF MIAMI   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; IXABEPILONE; LAPATINIB; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG COST; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; META ANALYSIS (TOPIC); METASTASIS; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SOLID TUMOR; THROMBOSIS; UNITED STATES;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG APPROVAL; FEMALE; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84867042331     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.9580     Document Type: Note

References (33)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
2. Herschbach P, Keller M, Knight L, et al: Psychological problems of cancer patients: A cancer distress screening with a cancer-specific questionnaire. Br J Cancer 91:504-511, 2004 (Pubitemid 39093570)
3. Gray R, Bhattacharya S, Bowden C, et al: Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 27:4966-4972, 2009
4. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247, 2010
5. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
6. Robert NJ, Diéras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260, 2011
7. O'Shaughnessy J, Miles D, Gray R, et al: A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 28:115s, 2010 (suppl 15; abstr 1005)
8. Brufsky AM, Hurvitz S, Perez E, et al: RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29:4286-4293, 2011
9. Cortes J, O'Shaughnessy J, Loesch D, et al: Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet 377:914-923, 2011
10. Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 101:1642-1649, 2009
11. Miles D, Harbeck N, Escudier B, et al: Disease course patterns after discontinuation of bevacizumab: Pooled analysis of randomized phase III trials. J Clin Oncol 29:83-88, 2011
12. Korn EL, Freidlin B, Abrams JS: Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol 29:2439-2442, 2011
13. Giordano SH, Buzdar AU, Smith TL, et al: Is breast cancer survival improving? Cancer 100:44-52, 2004
14. Albain KS, Nag SM, Calderillo-Ruiz G, et al: Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 26:3950-3957, 2008
15. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002 (Pubitemid 34651510)
16. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007 (Pubitemid 46972777)
17. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523, 2011
18. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006 (Pubitemid 46021510)
19. von Minckwitz G, du Bois A, Schmidt M, et al: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A german breast group 26/breast international group 03-05 study. J Clin Oncol 27:1999-2006, 2009
20. Johnston S, Pippen J Jr, Pivot X, et al: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27:5538-5546, 2009
21. Kaufman B, Mackey JR, Clemens MR, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529-5537, 2009
22. Riemsma R, Forbes CA, Kessels A, et al: Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat 123:9-24, 2010
23. Cella D, Wang M, Wagner L, et al: Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: Results from Eastern Cooperative Oncology Group Study 2100 (E2100). Breast Cancer Res Treat 130:855-861, 2011
24. Choueiri TK, Mayer EL, Je Y, et al: Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 29:632-638, 2011
25. Cortes J, Saura C, Atzori F: Risk of venous thromboembolism with bevacizumab in cancer patients. JAMA 301:1434-1435, 2009
26. Geiger-Gritsch S, Stollenwerk B, Miksad R, et al: Safety of bevacizumab in patients with advanced cancer: A meta-analysis of randomized controlled trials. Oncologist 15:1179-1191, 2010
27. Hapani S, Chu D, Wu S: Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: A meta-analysis. Lancet Oncol 10:559-568, 2009
28. Nalluri SR, Chu D, Keresztes R, et al: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 300:2277-2285, 2008
29. Ranpura V, Hapani S, Wu S: Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis. JAMA 305:487-494, 2011
30. Scappaticci FA, Skillings JR, Holden SN, et al: Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99:1232-1239, 2007 (Pubitemid 47299901)
31. Cortes J, Calvo V, Ramírez-Merino N, et al: Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis. Ann Oncol 23:1130-1137, 2012
32. Russell SD, Blackwell KL, Lawrence J, et al: Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 28:3416-3421, 2010
33. Dawood S, Shaikh AJ, Buchholz TA, et al: The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. Cancer 118:2780-2786, 2012